NYSE:WX - WuXi PharmaTech (Cayman) Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$45.91
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.

Receive WX News and Ratings via Email

Sign-up to receive the latest news and ratings for WX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
WebN/A
Phone+86-21-50461111

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

WuXi PharmaTech (Cayman) (NYSE:WX) Frequently Asked Questions

What is WuXi PharmaTech (Cayman)'s stock symbol?

WuXi PharmaTech (Cayman) trades on the New York Stock Exchange (NYSE) under the ticker symbol "WX."

Has WuXi PharmaTech (Cayman) been receiving favorable news coverage?

Media coverage about WX stock has been trending somewhat negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. WuXi PharmaTech (Cayman) earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.

What other stocks do shareholders of WuXi PharmaTech (Cayman) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other WuXi PharmaTech (Cayman) investors own include Baidu (BIDU), Himax Technologies (HIMX), Yelp (YELP), 3D Systems (DDD), VMware (VMW), Health Net (HNT), Synaptics (SYNA), salesforce.com (CRM), SolarCity (SCTY) and Endocyte (ECYT).

How do I buy shares of WuXi PharmaTech (Cayman)?

Shares of WX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact WuXi PharmaTech (Cayman)?

WuXi PharmaTech (Cayman)'s mailing address is 288 Fute Zhong Road China (Shanghai) Pilot Free Trade Zone, SHANGHAI, SHA 200131, China. The medical research company can be reached via phone at +86-21-50461111.


MarketBeat Community Rating for WuXi PharmaTech (Cayman) (NYSE WX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about WuXi PharmaTech (Cayman) and other stocks. Vote "Outperform" if you believe WX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Featured Article: Net Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel